炎症性腸疾患に対する血球成分除去療法の臨床(<特集>血球成分除去療法の新しい展開)

概要

論文の詳細を見る
We have been focused on the development of extracorporeal cytapheresis (CAP) for refractory inflammatory bowel disease (IBD) patients, which consists of ulcerative colitis (UC) and Crohn's disease (CD). In the present paper, we have reviewed the current status and the future view of this unique Japanese adjunct therapy. The current adaptation of CAP is limited only to active UC patients with steroid refractory background. We have recognized that a most important point to achieve a superior prognosis together with maintaining high quality of life is to judge their initial clinical response as soon as possible. In order to achieve this, it has been strongly required to establish an EBM-based protocol in order to determine an appropriate therapeutic regime for each patient. We also introduced the current status of the development of CAP for active CD patients, another major form of IBD. In the next step, we would like to propose an optimal and efficient treatment strategy, which induces the superior efficiency of CAP, including intensive CAP (I-CAP).
日本アフェレシス学会の論文
2009-02-28